President Trump announced the popular GLP-1 weight loss drugs would soon be more accessible to millions of Americans at a ...

One out of ten people don’t see the weight loss results they expect.

Multiple clinical trials have shown that GLP-1s are safe and effective for patients with obesity, diabetes and cardiovascular ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. People with diabetes who were taking GLP-1 ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

As GLP-1 drugs like Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy have spent the last couple of years skyrocketing in popularity—with no signs of slowing down—it was perhaps only a matter ...

Share on Pinterest A new generic of the GLP-1 drug Victoza, which is similar to popular medications like Ozempic, Wegovy, Mounjaro, and Zepbound, is now available in the United States.

Dushay is an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center. It makes my head spin to think about how much GLP-1s ...

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Trump administration decided to put the pilot on hold until at least 2027.

The Centers for Medicare & Medicaid Services will launch the Medicare GLP-1 Bridge in July 2026, offering some Part D beneficiaries temporary access to GLP-1 drugs for weight loss alongside coverage ...